Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 06BANGKOK7133, THAILAND PREPARING COMPULSORY LICENSE FOR HIV/AIDS DRUG

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06BANGKOK7133.
Reference ID Created Released Classification Origin
06BANGKOK7133 2006-11-28 23:48 2011-08-25 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Bangkok
VZCZCXRO0730
RR RUEHCHI RUEHDT RUEHHM RUEHNH
DE RUEHBK #7133/01 3322348
ZNR UUUUU ZZH
R 282348Z NOV 06
FM AMEMBASSY BANGKOK
TO RUEHC/SECSTATE WASHDC 3187
RUCNASE/ASEAN MEMBER COLLECTIVE
RUEHNE/AMEMBASSY NEW DELHI 4225
RUCPDOC/DEPT OF COMMERCE WASHDC
RUEHPH/CDC ATLANTA GA
RUEAUSA/USDOHHS WASHDC
UNCLAS SECTION 01 OF 02 BANGKOK 007133 
 
SIPDIS 
 
SENSITIVE 
 
SIPDIS 
 
STATE PASS USTR FOR B. WEISEL, S. MCCOY 
STATE PASS USPTO FOR K. HAUDA, K. FERRITER, P. SALMON 
HHS/OHGA FOR AMAR BHAT, ERIKA ELVANDER 
USDOC FOR JKELLY 
 
E.O. 12958:N/A 
TAGS: ECON ETRD KIPR TH
 
SUBJECT:  THAILAND PREPARING COMPULSORY LICENSE FOR HIV/AIDS DRUG 
 
 
(U) This document is sensitive but unclassified, please protect 
accordingly. 
 
1. (U) This is an action request, see paragraph 9. 
 
2. (SBU) Contacts at the Thai Department of Intellectual Property 
(DIP) told Embassy that the Ministry of Public Health (MoPH) may 
announce on December 1 that they plan to pursue a compulsory license 
for efavirenz, an antiretroviral used to treat HIV-positive 
patients.  The announcement would be timed to coincide with World 
AIDS Day on Friday. 
 
3. (SBU) Merck & Co., a U.S.-based pharmaceutical manufacturer, 
holds the patent for efavirenz in Thailand and distributes it 
locally under the trade name Stocrin.  Efavirenz is a first-line 
AIDS drug, used primarily for the five or ten percent of patients 
who have had an adverse reaction to other first-line combinations. 
Thailand widely uses a domestically produced generic antiretroviral 
known as GPO-vir to treat its large HIV-positive population; 
substituting efavirenz greatly increases the cost per patient. 
Merck estimates purchases of efavirenz account for approximately 25 
percent of expenditures on all antiretrovirals in Thailand. 
 
4. (SBU) Article 51 of the Thai Patent Act spells out procedures for 
a compulsory license.  The Act allows for an RTG ministry or 
department to "exploit any invention under any patent" for a variety 
of reasons, including "for the sake of other public interest", the 
justification the RTG will most likely use.  Merck's local legal 
counsel believes that the MoPH must apply to the DIP to issue the 
compulsory license and enter into royalty negotiations in advance of 
issuing the license.  The DIP, on the other hand, asserts that under 
Thai law, MoPH can publicly announce its plans to issue a compulsory 
license and negotiate the royalties afterwards.  Article 31 of the 
WTO TRIPS agreement would normally require MoPH to first request 
authorization from Merck to produce or import under "reasonable 
commercial terms", however, DIP says MoPH plans to skip that step 
using exceptions under Article 31(b) for "public non-commercial 
use".  The lead actor in importing generic product or ingredient 
would be the Government Pharmaceutical Organization, a 
revenue-earning state-owned enterprise whose activities may not 
qualify as public non-commercial use. 
 
Why this drug?  Why now? 
------------------------ 
 
5. (SBU) Merck's local representatives are perplexed why the MoPH 
has decided to break their patent on efavirenz.  As a middle-income 
country with a greater than one percent prevalence of HIV cases, 
Thailand qualifies for Merck's lowest price offered under its 
pricing policy.  Merck reports to us they sell the drug at a 
no-profit price to NGOs, approximately 1000 baht per month (USD 
27.50), less than half the price sold at in other middle income 
countries such as China and Brazil.  Merck also sells to the 
government for 1300 baht per month (USD 35.80), the higher price 
reflecting additional local costs imposed by the RTG. 
 
6. (SBU) It is unclear yet whether the MoPH would seek to import a 
generic version of the drug or produce it locally.  Merck believes 
an Indian generic firm may be able to supply efavirenz at a slightly 
lower cost, but believes the savings would be minimal and hardly 
worth the effort.  Contacts at the Government Pharmaceutical Office 
say they would need approximately a year to perform the necessary 
testing and receive approval to begin domestic production.  However, 
MoPH believes GPO could eventually produce a generic copy of 
efavirenz for 30 to 50 percent less cost than the original drug. 
 
7. (SBU) According to a MoPH source we believe credible, local 
public health NGOs instigated the proposal for the compulsory 
license and may be pushing the idea as much as a political test as 
for the possible cost savings to AIDS patients.  Although the MoPH's 
Department of Disease Control initially rejected the idea, the NGOs 
succeeded in submitting their proposal directly to the Minister. 
There still appears to be a lack of consensus within the MOPH on the 
wisdom of pursuing a compulsory license and it is not yet clear 
whether a final decision has been made to push ahead with the plan. 
DIP has expressed its own reservations and is sensitive to how a 
compulsory license could affect Thailand's image regarding 
intellectual property protection. 
 
8. (SBU) Embassy has been in contact with officials at Ministry of 
Commerce and Ministry of Foreign Affairs to ensure they are aware of 
 
BANGKOK 00007133  002 OF 002 
 
 
MoPH activities and the full implications of any actions they may 
take.  We understand an MoPH meeting will take place November 29 to 
discuss the issue further. 
 
9. (SBU) Embassy requests Washington agency guidance on how to 
proceed and what message we should communicate to the RTG on this 
matter.  We note that during FTA negotiations with Thailand the 
issue of pharmaceutical patents was highly controversial and 
engendered large protests.  Thailand is rightly proud of its efforts 
to slow the spread of AIDS and the Thai public looked dimly on the 
FTA's possible effects on access to antiretrovirals.  AIDS 
organizations and public health activists hold widespread sympathy 
in and out of the government and we suspect a compulsory license 
would meet with public approval.  A compulsory license case would be 
watched closely both in Thailand and globally to gauge USG reaction 
and commitment to the public health provisions in the WTO.  We are 
under no illusion that any USG action to prevent a compulsory 
license could be kept out of the public eye. 
ARVIZU